ClinicalTrials.gg

Program

PF-07258669

Its studies are led by Pfizer.

Furthest: phase 1, since Nov 9, 20204 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer40 open or runningphase 1since Nov 9, 2020Nov 9, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2020First study: phase 1 study in Healthy ParticipantsFirst studyNCT04628793 · 29 enrolled · United States
  2. Oct 13, 2021Phase 1 study in Healthy ParticipantsNCT05113940 · 120 enrolled · Belgium
  3. Nov 21, 2024Phase 1 study in HealthyNCT06706869 · 26 enrolled · United States
  4. Jul 18, 2025Phase 1 study in Healthy VolunteersNCT07086664 · 7 enrolled · United States, Canada, Japan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07086664Healthy Volunteers · United States, Canada, Japan1TerminatedJan 21, 20267
NCT06706869Healthy · United States1CompletedFeb 20, 202526
NCT05113940Healthy Participants · Belgium1CompletedJul 27, 2023120
NCT04628793Healthy Participants · United States1CompletedAug 25, 202129

How it is read

Names in the registry

  • “PF-07258669”, 4 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.